Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The cellular basis of protease-activated receptor 2–evoked mechanical and affective pain
Shayne N. Hassler, Moeno Kume, Juliet M. Mwirigi, Ayesha Ahmad, Stephanie Shiers, Andi Wangzhou, Pradipta R. Ray, Serge N. Belugin, Dhananjay K. Naik, Michael D. Burton, Josef Vagner, Scott Boitano, Armen N. Akopian, Gregory Dussor, Theodore J. Price
Shayne N. Hassler, Moeno Kume, Juliet M. Mwirigi, Ayesha Ahmad, Stephanie Shiers, Andi Wangzhou, Pradipta R. Ray, Serge N. Belugin, Dhananjay K. Naik, Michael D. Burton, Josef Vagner, Scott Boitano, Armen N. Akopian, Gregory Dussor, Theodore J. Price
View: Text | PDF
Research Article Neuroscience

The cellular basis of protease-activated receptor 2–evoked mechanical and affective pain

  • Text
  • PDF
Abstract

Protease-activated receptor 2 (PAR2) has long been implicated in inflammatory and visceral pain, but the cellular basis of PAR2-evoked pain has not been delineated. Although PAR2-evoked pain has been attributed to sensory neuron expression, RNA-sequencing experiments show ambiguous F2rl1 mRNA detection. Moreover, many pharmacological tools for PAR2 are nonspecific, acting also on the Mas-related GPCR family (Mrg) that are highly enriched in sensory neurons. We sought to clarify the cellular basis of PAR2-evoked pain. We developed a PAR2–conditional knockout mouse and specifically deleted PAR2 in all sensory neurons using the PirtCre mouse line. Our behavioral findings show that PAR2 agonist–evoked mechanical hyperalgesia and facial grimacing, but not thermal hyperalgesia, are dependent on PAR2 expression in sensory neurons that project to the hind paw in male and female mice. F2rl1 mRNA is expressed in a discrete population (~4%) of mostly small-diameter sensory neurons that coexpress the Nppb and IL31ra genes. This cell population has been implicated in itch, but our work shows that PAR2 activation in these cells causes clear pain-related behaviors from the skin. Our findings show that a discrete population of DRG sensory neurons mediate PAR2-evoked pain.

Authors

Shayne N. Hassler, Moeno Kume, Juliet M. Mwirigi, Ayesha Ahmad, Stephanie Shiers, Andi Wangzhou, Pradipta R. Ray, Serge N. Belugin, Dhananjay K. Naik, Michael D. Burton, Josef Vagner, Scott Boitano, Armen N. Akopian, Gregory Dussor, Theodore J. Price

×

Figure 7

NE- and 48/80-evoked thermal hyperalgesia is not mediated via PAR2+ sensory neurons.

Options: View larger image (or click on image) Download as PowerPoint
NE- and 48/80-evoked thermal hyperalgesia is not mediated via PAR2+ sens...
Mice were injected with PAR2 agonists and then latency to paw withdrawal was measured via the Hargreaves test 1, 3, 5, 24, and 48 hours after hind paw injection. Baseline (BL) measures were obtained before administering 2AT, 48/80, or NE. When compared with F2rl1floxPirt+/+ mice, F2rl1floxPirtCre mice showed decreased thermal hyperalgesia in response to only 2AT (30 pmol) (A) but not to 48/80 (6.5 nmol) (B) or NE (10 units) (C). Effect size is determined by calculating the cumulative difference between the baseline value and the value for each time point. *P < 0.05 compared with F2rl1floxPirt+/+ or F2rl1floxPirtCre groups. #P < 0.05 compared with baseline measures. n = 4 for F2rl1floxPirt+/+ and F2rl1floxPirtCre groups treated with 2AT and 48/80, and n = 7 for F2rl1floxPirt+/+ and F2rl1floxPirtCre groups treated with NE. Data are expressed as mean ± SEM. Two-way ANOVA with Holm-Šidák and Dunnett’s multiple comparisons #P < 0.05, ##P < 0.01, and ###P < 0.001. Unpaired t test *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts